Stevanato Group S.p.A. (NYSE:STVN), a global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has secured €200 million in financing through agreements with BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM. These fundings are intended to support the Company's ongoing capital expenditure projects in Cisterna di Latina (Italy) and Fishers (Indiana, U.S.).

The financing agreements bolster Stevanato Group's capacity expansion efforts and the scaling of commercial production to support customers' growing biologics programs. CDP has committed €50 million to enhance the production of pre-filled syringes and set-up future capacity for ready-to-use (RTU) cartridges at Stevanato Group's Italian plant in Cisterna di Latina. Additionally, BNL BNP Paribas has provided €100 million, and Banco BPM has contributed €50 million, both aimed at scaling pre-filled syringe production at the company's facilities in North America (Indiana) and Italy, as well as completing the ongoing construction for device manufacturing in Fishers.